find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
10
Clinical Trials
Skin and Soft Tissue
N/A
Enrolling
Skin and Soft Tissue
Phase III
Enrolling
nct/study# NCT06112314 / IMC-F106C-301
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Learn More
Skin and Soft Tissue
Phase II/III
Enrolling
nct/study# NCT06947928 / MCC-2021-01
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial of IFx-Hu2.0 as An Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma
Learn More
Skin and Soft Tissue
Phase II
Enrolling
nct/study# NCT06594991 / MSK-24-166
A Phase 2 study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma
Learn More
Skin and Soft Tissue
Phase III
Enrolling
nct/study# NCT06246916 / R3767-ONC-22122
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
Learn More
Skin and Soft Tissue
Phase III
Enrolling
nct/study# NCT06264180 / RP1-104
A Randomized, Multicenter, Phase 3 Clinical Trial of Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 Containing Treatment Regimen
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.